Several other research analysts have also weighed in on the company. BMO Capital Markets cut their target price on VBI Vaccines to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 18th. Oppenheimer set a $5.00 target price on VBI Vaccines and gave the stock a “buy” rating in a research report on Wednesday, June 19th. Finally, Zacks Investment Research raised VBI Vaccines from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research report on Thursday, May 9th.
Shares of VBIV stock traded down $0.04 during mid-day trading on Thursday, hitting $0.69. 397,824 shares of the company’s stock were exchanged, compared to its average volume of 1,091,154. VBI Vaccines has a fifty-two week low of $0.57 and a fifty-two week high of $2.78. The company has a 50-day simple moving average of $0.97. The company has a current ratio of 1.99, a quick ratio of 1.94 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $67.57 million, a PE ratio of -0.71 and a beta of 0.44.
In other news, major shareholder Life Sciences Maste Perceptive bought 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were acquired at an average cost of $0.62 per share, with a total value of $620,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jeff Baxter acquired 144,000 shares of the business’s stock in a transaction on Wednesday, June 19th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $105,120.00. Following the completion of the transaction, the chief executive officer now directly owns 458,255 shares of the company’s stock, valued at $334,526.15. The disclosure for this purchase can be found here. Insiders purchased a total of 1,160,000 shares of company stock worth $739,600 over the last ninety days. Corporate insiders own 10.50% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in VBIV. United Services Automobile Association purchased a new position in VBI Vaccines in the fourth quarter valued at about $41,000. Weil Company Inc. purchased a new position in VBI Vaccines in the first quarter valued at about $41,000. Massey Quick Simon & CO. LLC purchased a new position in VBI Vaccines in the first quarter valued at about $42,000. Bank of New York Mellon Corp purchased a new position in VBI Vaccines in the fourth quarter valued at about $51,000. Finally, Two Sigma Investments LP raised its position in VBI Vaccines by 192.5% in the fourth quarter. Two Sigma Investments LP now owns 49,936 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 32,861 shares during the period. 51.42% of the stock is currently owned by institutional investors.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
See Also: Bollinger Bands
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.